Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Outlook Therapeutics Inc (OTLK)

Outlook Therapeutics Inc (OTLK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 29,763
  • Shares Outstanding, K 30,103
  • Annual Sales, $ 8,150 K
  • Annual Income, $ -34,520 K
  • 60-Month Beta -1.07
  • Price/Sales 3.70
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.88
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/13/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -0.07
  • Number of Estimates 1
  • High Estimate -0.07
  • Low Estimate -0.07
  • Prior Year -0.60
  • Growth Rate Est. (year over year) +88.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.85 +12.31%
on 01/28/20
1.12 -14.77%
on 01/23/20
-0.09 (-8.21%)
since 01/17/20
3-Month
0.52 +83.58%
on 12/30/19
1.74 -45.14%
on 12/03/19
-0.10 (-9.09%)
since 11/20/19
52-Week
0.52 +83.58%
on 12/30/19
9.36 -89.80%
on 02/21/19
-8.65 (-90.06%)
since 02/20/19

Most Recent Stories

More News
Biotechs Move Forward Developing Latest Targeted Therapies for Acute Myeloid Leukemia

So it is not surprising that there is a lot of money and research resources being devoted to find new therapies for Acute Myeloid Leukemia (AML), many of which are in the targeted drugs arena. AML is the...

MBRX : 0.79 (+2.27%)
BOLD : 59.97 (-0.02%)
OTLK : 0.95 (-3.45%)
AXSM : 92.59 (+0.48%)
QURE : 63.59 (-1.99%)
Biotech Brief: Reports Forecast Continued Rise in Revenues for Diabetic Ulcer Treatment Market

According to a report from Grand View Research, the global diabetic foot ulcer treatment market size is expected to reach a value of USD 6.82 billion by 2025, according to a new report by Grand View Research,...

HOTH : 4.41 (-2.47%)
MTP : 0.61 (-1.58%)
TEVA : 13.31 (-1.04%)
ACST : 0.56 (unch)
ACST.VN : 0.745 (-1.97%)
OTLK : 0.95 (-3.45%)
Hottest Wall Street Stories: What's Up, What's Down

Tariff tantrums hit the broader stock markets last month, leading to the worst May after 2010. Below we discuss these in detail and the impact on the stock world from these events.

QCOM : 89.47 (-1.20%)
GM : 35.29 (+1.06%)
F : 8.03 (+0.37%)
FCAU : 13.30 (+0.68%)
OESX : 5.52 (-5.96%)
AAPL : 320.30 (-1.03%)
PES : 0.16 (-5.36%)
HK : 0.16 (-5.00%)
NVDA : 308.70 (-1.91%)
MU : 59.00 (-1.65%)
RGSE : 0.0073 (-12.05%)
OTLK : 0.95 (-3.45%)
ACA : 45.60 (+1.88%)
FTDR : 46.53 (+2.11%)
OBLN : 1.85 (-0.54%)
Outlook Therapeutics Announces Addition of Jennifer M. Kissner, Ph.D. as Senior Vice President, Clinical Development

Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the "Company"), a clinical-stage biopharmaceutical company focused on developing its lead clinical program, ONS-5010, a proprietary ophthalmic bevacizumab product...

CLSD : 2.72 (-1.81%)
OTLK : 0.95 (-3.45%)
Healthcare Investment Opportunities You Can't Miss

HENDERSON, NV / ACCESSWIRE / February 13, 2019 / When looking for great growth opportunities to invest in, look no further than the healthcare sector. Healthcare stocks have consistently produced big winners...

OTLK : 0.95 (-3.45%)
ZYNE : 4.81 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade OTLK with:

Business Summary

Outlook Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focuses on developing ONS-5010 which is a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration which is in clinical stage. Outlook Therapeutics Inc., formerly known as...

See More

Key Turning Points

2nd Resistance Point 1.02
1st Resistance Point 0.99
Last Price 0.95
1st Support Level 0.93
2nd Support Level 0.91

See More

52-Week High 9.36
Fibonacci 61.8% 5.98
Fibonacci 50% 4.94
Fibonacci 38.2% 3.90
Last Price 0.95
52-Week Low 0.52

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar